GLP-RT, in brief. GLP-RT is a synthetic 39-residue peptide that acts on three receptors at once: the GIP receptor, the GLP-1 receptor and the glucagon receptor. Those three receptors normally answer to three separate hormones, and each drives a different part of how an animal handles fuel. GIP and GLP-1 receptor signalling raises insulin release when glucose is high and lowers food intake. Glucagon receptor signalling pushes liver and fat tissue to mobilise and burn stored fuel, which raises energy expenditure. Combining all three activities in one molecule lets a single compound pull on intake and on expenditure at the same time, which is the whole idea behind the design. In rodents fed a high-fat diet, that combination lowered body weight, serum lipids and liver enzyme markers. A C20 fatty diacid chain attached to one lysine lets the peptide bind albumin, which is the structural reason its action is long rather than brief. NextGenPeps supplies GLP-RT as 10 mg, 20 mg and 50 mg lyophilised research vials for laboratory use only.
What does GLP-RT do?
It switches on three metabolic receptors with one molecule. Two of them, the GIP and GLP-1 receptors, belong to the incretin system that links a meal to insulin release and to reduced feeding. The third, the glucagon receptor, does close to the opposite job in the liver: it releases stored fuel and raises the rate at which fuel is burned. A compound that engages all three can lower intake and raise expenditure in the same experiment, rather than acting on only one side of the balance.[1,2]
In cell and rodent models that comes down to three things:
Incretin signalling. GIP and GLP-1 receptor activation raises glucose-dependent insulin secretion from islet cells and lowers food intake in rodents.[1,9]
Glucagon signalling. Glucagon receptor activation in liver and adipose tissue raises energy expenditure and lipid turnover, which is the arm the two incretin receptors do not supply.[1]
Measured outcomes in animals. In diet-induced obese rodents, treatment lowered body weight, serum lipids and liver enzyme markers against vehicle controls.[1,3,4,5]
NextGenPeps supplies GLP-RT for in vitro research and approved animal studies only. It is not sold as a drug, supplement or diagnostic.
How does GLP-RT work?
All three receptors are class B G-protein-coupled receptors, and all three run the same core cascade. The peptide binds the receptor, the receptor couples to the Gs protein, the cell raises cyclic AMP, and protein kinase A carries the signal onward. What differs is where each receptor sits. GLP-1 and GIP receptors sit on islet cells and on neurons in feeding circuits; glucagon receptors sit mostly on hepatocytes. One shared second messenger, three different tissues, three different readouts.[1,9]

Figure 1. How GLP-RT signals at three receptors.
GLP-RT engages the GIP, GLP-1 and glucagon receptors, each coupling through Gs, cyclic AMP and protein kinase A to a different tissue readout. Receptor potencies are from Coskun et al. 2022 as quoted in Katsi et al. 2025. Schematic, not to scale.[1,2]
The three potencies are not equal, and the spread matters for experimental design. At cloned human receptors the half-maximal effective concentration was 0.0643 nM at the GIP receptor, 0.775 nM at the GLP-1 receptor and 5.79 nM at the glucagon receptor, a range of about 90-fold from the most to the least potent.[1,2] Binding affinities follow the same order. Because the glucagon receptor is the least potent of the three, the glucagon arm of the pharmacology only comes fully into play at higher concentrations, which is worth holding in mind when comparing results across assay systems.

Figure 2. GLP-RT receptor potency.
Half-maximal effective concentrations at the cloned GIP, GLP-1 and glucagon receptors, on a log scale. A shorter bar means greater potency. In vitro values only, not interchangeable with other assay systems.[1,2]
What did GLP-RT do in animal studies?
Rodents on a high-fat diet lost weight, and their blood lipids and liver enzymes moved a long way toward the values of lean controls. This is the part of the record with the most concrete numbers, so it is worth taking in detail.
In male Sprague-Dawley rats made obese on a high-fat, high-sucrose diet for eight weeks, four weeks of daily subcutaneous GLP-RT at 25 nmol/kg (n=7 per group) changed serum lipids against the vehicle group: total cholesterol fell from 232.3 to 105.9 mg/dL, triglycerides from 112.1 to 30.4 mg/dL, LDL from 171.6 to 51.3 mg/dL, and HDL rose from 38.3 to 65.8 mg/dL, all at p < 0.0001. Liver enzymes moved in the same direction, with AST at 52.43 U/L against 97.14 U/L in the vehicle group and alkaline phosphatase at 58.29 U/L against 111.71 U/L. Hepatic markers of oxidative stress and inflammation also fell and hepatic glutathione rose.[3]

Figure 3. What GLP-RT did in diet-induced obese rats.
Serum lipids after four weeks of daily GLP-RT at 25 nmol/kg against vehicle control, n=7 per group, in male Sprague-Dawley rats on a high-fat, high-sucrose diet. Values are taken from the published tables of Al-Shibil and Kadhim 2026.[3]
A companion report from the same rat model records lower body weight, lower blood glucose and lower serum insulin in the treated group against untreated obese rats, with glucose at 85.71 mg/dL after four weeks against 107.00 mg/dL before treatment in the same animals.[4]
Head-to-head work in db/db mice puts the triple agonist against narrower agonists. Animals received 10 nmol/kg daily by subcutaneous injection for 10 weeks (n=6 per group), compared with a GLP-1-only agonist and a GLP-1 plus GIP dual agonist. At 10 weeks the triple agonist group had the lowest body weight and the lowest food intake of the three, followed by the dual agonist and then the GLP-1-only agonist. Glycated haemoglobin, ALT, AST, total cholesterol, triglycerides and LDL all improved most in the triple agonist group, as did renal inflammatory and fibrotic markers.[5]
Two further rodent findings round out the picture. In obese mice, GLP-RT slowed gastric emptying in a dose-dependent way from 0.3 nmol/kg upward, and over 10 days of daily dosing at 10 nmol/kg it produced a larger fall in body weight and in cumulative food intake than a GLP-1-only comparator or a long-acting glucagon receptor agonist, given alone or together (n=5 per group); the gastric emptying delay itself was attenuated by day 10.[6] In a 31-day diet-induced steatohepatitis mouse model, dosing over the final two weeks lowered body weight, liver enzymes, hepatic lipids and inflammatory markers against vehicle in female mice.[7]
For class context, a different GLP-1, GIP and glucagon triagonist peptide (not GLP-RT) given at 5 or 10 nmol/kg daily for 27 days to diet-induced obese mice produced body weight falls of 18.55 ± 1.28% and 29.64 ± 1.29% in females and 25.33 ± 1.67% and 42.82 ± 1.56% in males, with resolution of steatohepatitis in most animals at the higher dose.[8] Those figures belong to that molecule, not to GLP-RT, and are included only to show the range reported for triple agonism in rodents.
GLP-RT vs GLP-S and GLP-TZ: receptor targets
The three differ in how many of the three receptors they engage. Nothing below compares how well they work; it is a map of targets and class, not of effect.
GLP-S. GLP-1 receptor only. Class: single incretin receptor agonist.
GLP-TZ. GLP-1 receptor plus GIP receptor. Class: dual incretin receptor agonist.
GLP-RT. GLP-1 receptor plus GIP receptor plus glucagon receptor. Class: triple receptor agonist, two incretin receptors and one non-incretin receptor.[1,2]
The practical consequence for a study design is which arms of the pharmacology are present. Only the triple agonist carries a glucagon receptor arm, so only it can be used to ask what that arm adds on top of incretin signalling in the same animal.
What is GLP-RT made of?
It is a single chain of 39 amino acids with a C-terminal amide, built on an incretin-family backbone and then modified in three ways to make it stable and long acting.[1]
Non-natural residues. Two aminoisobutyric acid (Aib) substitutions at positions 2 and 20 and an alpha-methyl-leucine at position 13 stiffen the helix and block the proteases that clear native incretins quickly.
Fatty acid chain. A C20 fatty diacid is attached to the lysine at position 17 through a gamma-glutamate and an AEEA spacer. The chain binds albumin, which is what converts a short-lived peptide into a long-acting one.
Composition. Molecular formula C221H342N46O68, molecular weight 4731.33.
Sequence (one-letter, with modifications): Y-Aib-QGTFTSDYSI-(alpha-Me-Leu)-LDK-K(C20 diacid-gammaGlu-AEEA)-AQ-Aib-AFIEYLLEG-GPSSGAPPPS-NH2.
GLP-RT at a glance
Compound: GLP-RT
Class: Synthetic lipidated peptide; agonist at the GIP, GLP-1 and glucagon receptors
Sequence: 39 residues, C-terminal amide, two Aib substitutions, one alpha-methyl-leucine, C20 fatty diacid on Lys17 via gamma-glutamate and AEEA
Molecular formula: C221H342N46O68
Molecular weight: 4731.33
Receptor potency (EC50): GIP receptor 0.0643 nM, GLP-1 receptor 0.775 nM, glucagon receptor 5.79 nM[1,2]
Strength per vial: 10 mg, 20 mg or 50 mg
Identity and purity: 99.72% on the 10 mg lot and 99.77% on the 20 mg lot (independent labs, September 25, 2026); 99.805% on the 50 mg lot (March 18, 2026). Certificates for every lot are published in the COA library
Endotoxin: Under 0.05 EU/ml on the 10 mg and 20 mg lots, tested per USP <85>. The 50 mg lot was not endotoxin tested
Appearance: White lyophilised powder, sealed vial
Reconstitution: Sterile or bacteriostatic water
Regulatory status: Research use only. Not an approved drug, supplement or diagnostic
Is GLP-RT FDA approved?
No. GLP-RT is a research material, not an approved drug. It is supplied for in vitro work and approved animal studies only, and it is not sold as a drug, supplement or diagnostic. Nothing on this page should be read as a statement about the regulatory status of any other compound.
What is GLP-RT used to study?
The reason to reach for a triple agonist rather than a narrower one is almost always to isolate what the glucagon receptor arm contributes. Each use below leans on a different part of the molecule.
Receptor pharmacology. Cells expressing a single cloned receptor are used to measure potency, selectivity and cyclic AMP output at each of the three targets.[1]
Diet-induced obesity in rodents. Body weight, food intake, energy expenditure and body composition in high-fat-fed mice and rats.[1,3,6]
Hepatic lipid handling and steatohepatitis models. Liver enzymes, hepatic lipid content and inflammatory and fibrotic markers in diet-induced models.[3,7]
Comparative incretin pharmacology. Head-to-head rodent studies against GLP-1-only and GLP-1 plus GIP agonists, used to separate what each added receptor arm does.[5]
Gastrointestinal transit. Gastric emptying in mice, including how the effect changes with repeated dosing.[6]
Buying GLP-RT for research: what each vial includes
Every lot is tested by independent labs and the certificate of analysis is published in the NextGenPeps COA library. The 10 mg and 20 mg lots were analysed on September 25, 2026: identity by LC-MS/MS, purity by RP-HPLC at 214 nm, content by HPLC quantitation, and endotoxin per USP <85>. The 50 mg lot was analysed on March 18, 2026 by UHPLC with mass spectrometry, and that lot carries no endotoxin result.
Verified identity and purity. 99.72% (10 mg), 99.77% (20 mg) and 99.805% (50 mg); every certificate is published in the COA library.
Endotoxin, where tested. Under 0.05 EU/ml on the 10 mg and 20 mg lots. No endotoxin test was run on the 50 mg lot, so no endotoxin claim is made for it.
US-based fulfilment. Orders ship within 24 hours from the United States, with free US shipping on orders over $150.
Research use only. GLP-RT is sold strictly for in vitro and approved animal research. It is not for human or veterinary use.
GLP-RT handling, storage and analytical notes
Format. Supplied as lyophilised powder in a sealed vial and reconstituted with sterile or bacteriostatic water. No dosing instructions are supplied, and none should be inferred from the animal studies above.
Storage. Keep the sealed vial cold, at 2 to 8 degrees C, or at minus 20 degrees C for longer holding, protected from light. After reconstitution hold the solution at 2 to 8 degrees C and avoid repeated freeze-thaw cycles. The lot certificates record a storage temperature of 2 to 8 degrees C.
Counterion. Lipidated peptides purified by RP-HPLC commonly carry a residual trifluoroacetate counterion, which adds to total weighed mass and can shift apparent solubility. Quantitative work should calibrate against net peptide content rather than gross vial weight.
Solubility. The C20 diacid chain makes the molecule markedly more lipophilic than a plain peptide of similar length, and it binds albumin, so assay buffers containing serum or albumin will not report the same free concentration as protein-free buffers.
Cross-assay comparison. The EC50 values above come from cloned single-receptor systems. Potency ratios measured in primary cells or in tissue will not match them exactly, so comparisons should be made within one assay format.[1]
What is not established about GLP-RT
The size of the glucagon contribution. The glucagon receptor is the least potent of the three targets, and how much of the rodent outcome it accounts for at any given exposure has not been resolved.[1]
Transfer between species and models. The numbers above come from rats and mice on specific diets, at specific doses, over weeks. They do not transfer to other species, other models or other exposures.[3,5,6,7]
Long-term and tissue-level effects. Rodent studies to date run for weeks, not for the lifespan of the animal, so durability of the changes and any late tissue effects are unknown.[3,5]
Research-grade material. Research-grade peptide is not manufactured to the potency, sterility or stability standards of a pharmaceutical product, and no stability dataset is supplied with it.
Research Use Only. The statements made within this website have not been evaluated by the US Food and Drug Administration. These materials are not intended to diagnose, treat, cure or prevent any disease and are not intended for human or veterinary use. Studies described on this page are reported for scientific context and are not guidance of any kind.